State policy guides
Plain-language guides organize federal status, state-level developments, and the distinction between proposed, enacted, and administrative action. They are built to support careful reading of a changing legal picture.
Independent information services
Guides, comparisons, and research summaries for understanding ibogaine in the United States—without treating unsettled law, incomplete evidence, or safety concerns as simple answers.
What Junara provides
Junara is an independent resource on the evolving U.S. landscape for ibogaine, including law, research, and safety evidence. It helps people distinguish enacted policy and primary sources from unsupported claims.
Our state-by-state starting point brings those questions into one place. The work is informational rather than clinical: it is designed to make terminology, legal boundaries, research questions, and uncertainty easier to see.
Our approach is grounded in the principles described in Junara’s mission and sourcing approach: independence, primary sources, plain language, safety awareness, and legal clarity.
Information offerings
These are research and decision-support materials, not treatment recommendations or clinical services.
Plain-language guides organize federal status, state-level developments, and the distinction between proposed, enacted, and administrative action. They are built to support careful reading of a changing legal picture.
Comparison pages and a working glossary separate terms that are often used loosely. For a broader look at options discussed outside conventional care, see ibogaine alternatives.
Evidence summaries describe what a source says, what it does not establish, and where questions remain. Context on claims involving dependence can be compared with material on ibogaine for addiction treatment.
Structured questions help readers identify legal, medical, and evidence-related issues before drawing conclusions. A separate overview of reported ibogaine therapy benefits can help distinguish claims from the evidence needed to support them.
How to read the material
Ibogaine is listed as a Schedule I controlled substance under U.S. federal law; the DEA’s controlled-substances schedule is a useful primary reference for that classification. A state discussion does not remove the need to understand federal law.
Useful information makes its limits visible.
Health claims also need careful framing. Discussion of neurodegenerative conditions should not be treated as established care; the National Institute on Aging’s Alzheimer’s overview describes the condition and current research context. Related claim-focused material includes ibogaine and Alzheimer’s discussions and information framed around ibogaine for dementia.
A cautious sequence
The framework below is intended for evaluating information, not for choosing or arranging treatment. It keeps legal status, research evidence, and safety considerations in their own lanes.
Where discussions turn to services beyond the United States, materials such as ibogaine treatment centers in Mexico should be read with the same attention to source quality, legal context, and limits of promotional claims.
Common questions
No. Junara provides independent information about policy, research, and safety considerations. It does not diagnose conditions, recommend treatment, or replace individualized advice from appropriately qualified professionals.
State developments may shape public discussion, research activity, or local policy, while federal status remains an important part of the legal context. The goal is to make those layers visible rather than collapse them into a single claim.
Summaries aim to distinguish what is known, what is preliminary, and what is not established. Background on the substance itself can be checked against the general ibogaine reference entry, while Junara’s materials emphasize source context and uncertainty.
Start with the landscape
Junara’s materials are designed to support a more careful reading of ibogaine policy, research, and safety information in the United States.